4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.255
-0.375 (-10.33%)
Mar 31, 2025, 1:23 PM EDT - Market open

4D Molecular Therapeutics Stock Forecast

FDMT's stock price has decreased by -89.58% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 9 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 35, with a low estimate of 6.00 and a high estimate of 58. The average target predicts an increase of 975.27% from the current stock price of 3.26.

Analyst Consensus: Buy
Target Low Average Median High
Price $6.00 $35 $36 $58
Change +84.33% +975.27% +1006.0% +1681.9%

Analyst Ratings

The average analyst rating for 4D Molecular Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Oct '24Nov '24Dec '24Jan '25Feb '25Mar '25
Strong Buy 445544
Buy 444444
Hold 111111
Sell 011111
Strong Sell 000000
Total 91011111010

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
B of A Securities
B of A Securities
Strong Buy
Maintains
$42$40
Strong Buy Maintains $42$40 +1,128.88% Mar 10, 2025
Chardan Capital
Chardan Capital
Strong Buy
Maintains
$30$28
Strong Buy Maintains $30$28 +760.22% Mar 4, 2025
RBC Capital
RBC Capital
Buy
Maintains
$39$35
Buy Maintains $39$35 +975.27% Mar 3, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$36
Strong Buy Reiterates $36 +1,005.99% Mar 3, 2025
Chardan Capital
Chardan Capital
Strong Buy
Maintains
$39$30
Strong Buy Maintains $39$30 +821.66% Feb 11, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
4.12M
from 37.00K
Increased by 11,029.73%
Revenue Next Year
5.94M
from 4.12M
Increased by 44.15%
EPS This Year
-3.67
from -2.98
EPS Next Year
-4.01
from -3.67
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
13.61M18.04M3.13M20.72M37.00K4.12M5.94M32.18M
Revenue Growth
94.85%32.52%-82.65%562.29%-99.82%11,029.73%44.15%442.15%
EPS
-8.82-2.57-3.32-2.58-2.98-3.67-4.01-3.95
EPS Growth
--------
Forward PE
--------
No. Analysts -----1295
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 21.0M 21.0M 81.9M
Avg 4.1M 5.9M 32.2M
Low n/a n/a 2.4M

Revenue Growth

Revenue Growth 20252026202720282029
High
56,656.8%
410.0%
1,279.7%
Avg
11,029.7%
44.1%
442.1%
Low - -
-60.4%

EPS Forecast

EPS 20252026202720282029
High -3.21 -3.10 -3.65
Avg -3.67 -4.01 -3.95
Low -4.15 -5.30 -4.52

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.